Malignant Pleural Mesothelioma: Present Status and Future Directions

Malignant pleural mesothelioma is a life-threatening neoplasm of the mesothelium, the layer of tissue that covers many organs in the human body. The incidence of this type of neoplasm is gradually ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Analysis of Therapies for Malignant Pleural Mesothelioma: Words that Count, Numbers that Speak

Pp. 515-520 (6)

Francesca Fiorentino and Tom Treasure

Abstract

Evaluating the benefit of therapies for malignant mesothelioma is a quite difficult task. The difficulty lies in identifying patients who might have benefited from a given treatment but knowingly did not receive it. Unless these 'suitable' patients have been identified in advance of any treatment and the process of allocation to one treatment or another is without bias. This is best achieved by randomization and in our view, for relatively small trials with heterogeneous patients, that is best done with the additional step of minimization.

Keywords:

Observational data, outcome, sample size, selection bias, statistical analysis.

Affiliation:

National Heart and Lung Institute, Dept. of Cardiothoracic Surgery, Imperial College London, Du Cane Road W12 0NN, London, United Kingdom.